TORONTO, Feb. 20, 2018 /CNW/ - Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) ("Xanthic") is excited to announce the appointment of Carli Posner as the Chair of the Xanthic board of directors. Ms. Posner is one of the first females to be appointed as the Chair of a public company in the cannabis sector. Ms. Posner is also the first female Principal, Publisher and CEO of a Canadian media company, Notable Life. Over the course of her career, Ms. Posner has generated over $100 million in partnerships in the marketplace.
Tim Moore, the CEO of Xanthic, commented, "We are thrilled to have Carli Posner alongside our other colleagues for the upcoming year. Carli's versatile career and experience perfectly compliments our strategy and mission to grow Xanthic's market share. At Xanthic, we are committed to pushing the boundaries of innovation and growing inclusion in the cannabis technology industry."
Carli Posner, commented, "I am proud to be part of a transformative organization that is leading in both cutting edge technology and inclusion, which is paramount for global impact. I am thrilled to be contributing to their momentum and ground-breaking approach to cannabis technology."
Xanthic, through its wholly-owned operating subsidiary, Xanthic Biopharma Limited, provides valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis, and cannabis-infused products which deliver consistent THC and/or CBD levels. Using a proprietary process, Xanthic allows its strategic partners to deliver superior cannabinoid solubility and consistency versus competitive infused products.
Xanthic's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulation S under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.
SOURCE Xanthic BioPharma